Edition:
United States

Celgene Corp (CELG.O)

CELG.O on Nasdaq

108.28USD
2:54pm EDT
Change (% chg)

$2.10 (+1.98%)
Prev Close
$106.18
Open
$106.02
Day's High
$108.64
Day's Low
$105.56
Volume
4,178,204
Avg. Vol
4,511,015
52-wk High
$136.40
52-wk Low
$92.98

CELG.O

Chart for CELG.O

About

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology... (more)

Overall

Beta: 1.22
Market Cap(Mil.): $82,247.19
Shares Outstanding(Mil.): 774.60
Dividend: --
Yield (%): --

Financials

  CELG.O Industry Sector
P/E (TTM): 51.37 42.42 37.52
EPS (TTM): 2.07 -- --
ROI: 8.52 -9.34 14.48
ROE: 28.44 -9.70 15.65

Celgene drug fails to extend survival in lymphoma study

Celgene Corp said on Monday that its flagship drug Revlimid failed to extend survival as a maintenance therapy for a type of blood cancer after patients had responded to prior treatment.

Jul 25 2016

Celgene drug fails to extend survival in lymphoma study

July 25 Celgene Corp said on Monday that its flagship drug Revlimid failed to extend survival as a maintenance therapy for a type of blood cancer after patients had responded to prior treatment.

Jul 25 2016

BRIEF-Celgene and LYSARC provide update on the phase III study

* Interim analysis of overall survival, a key secondary endpoint, showed no benefit in revlimid

Jul 25 2016

CORRECTED-BRIEF-Jounce Therapeutics to collaborate with Celgene to develop immuno-oncology therapies

* Jounce Therapeutics says to receive upfront payment of $225 million and $36 million equity investment, up to $2.3 billion in future milestone payments

Jul 19 2016

UPDATE 2-Medivation agrees to open its books to Sanofi

July 5 U.S. cancer drug company Medivation Inc said on Tuesday it had agreed to provide confidential information to French pharmaceutical company Sanofi SA as part of exploring a sale that would be open to other bidders.

Jul 05 2016

BRIEF-Celgene announces additional $3 bln share repurchase authorization

* Celgene announces additional $3 billion share repurchase authorization

Jun 15 2016

BRIEF-Bionor Pharma says possible extension of alliance with Celgene

* Says scientific collaborations include possible extension of ongoing collaboration with Celgene Corporation Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jun 13 2016

BRIEF-Acceleron, Celgene says data with Luspatercept show increases in hemoglobin levels

* Acceleron and Celgene announce updated results from an ongoing Phase 2 study of Luspatercept in beta-thalassemia presented at the 21st congress of the European Hematology Association

Jun 10 2016

J&J myeloma drug, in combo regimen, delays worsening of the disease

Johnson & Johnson's therapy for advanced multiple myeloma sharply reduced the risk of disease progression when taken with two standard treatments for the blood cancer, according to research the company hopes will pave the way for wider use of the treatment.

Jun 05 2016

Competitors

  Price Chg
Takeda Pharmaceutical Co Ltd (4502.T) ¥4,548 +35.00
Eisai Co., Ltd (4523.T) ¥6,213 +10.00
Johnson & Johnson (JNJ.N) $124.84 -0.31
Novartis AG (NOVN.S) CHF81.90 -0.60
Pfizer Inc. (PFE.N) $36.82 -0.01
Roche Holding Ltd. (ROG.S) CHF249.30 -1.00
Roche Holding Ltd. (RO.S) CHF250.00 -1.25
Merck & Co., Inc. (MRK.N) $58.55 +0.19
Sanofi SA (SASY.PA) €76.70 +0.13
AstraZeneca plc (AZN.L) 4,690.00p +51.50

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
$20.00
Provider : New Constructs, LLC
$25.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : Wright Reports
$75.00
Provider : ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.